Utilizing small molecules R1-1 and B02 to inhibit RAD51, which plays an important role in homologous recombination, has led to radiotherapy and chemotherapy sensitization in glioma and breast cancer, respectively. The gene discussed is RAD51; the disease is breast cancer.